Esperion Therapeutics, Inc. was acquired by Essence Parent Inc. on May 1, 2026, according to the Form 8-K Esperion Therapeutics, Inc. filed with the SEC. The filing states a price of $100 million. It is the only completed acquisition Essence Parent Inc. reported under Item 2.01 in the last twelve months (Form 8-K, July 13, 2026).
1 companies announced an acquisition this week.
Companies in an acquisition this week, and the deal. Before you unlock: the company, the deal and what is inside. After: every way we found to reach the company, and anyone a source names. A team joining the buyer is labelled only when the filing itself says so.
| Bowman Consulting Group Ltd. | agreed to be acquired by Prive Parent, Inc. |
Competing with, selling to or investing in Essence Parent Inc. after this deal? See the free Snapshot first.
Free to see. No signup.
Essence Parent Inc. completed its acquisition of Esperion Therapeutics, Inc. on 2026-05-01, according to the Form 8-K Esperion Therapeutics, Inc. filed with the SEC on 2026-07-13. The filing states a price of $100 million. Esperion Therapeutics, Inc. filed the report because the deal made it part of Essence Parent Inc..
| Acquirer | Essence Parent Inc. |
|---|---|
| Acquired | Esperion Therapeutics, Inc. |
| Completed | 2026-05-01 |
| Price stated in the filing | $100 million |
| Reported by | Esperion Therapeutics, Inc. (ESPR), the company acquired |
| Filing | Form 8-K, filed 2026-07-13 |
Want the whole picture on Essence Parent Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Essence Parent Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Essence Parent Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
As previously disclosed, on May 1, 2026, Esperion Therapeutics, Inc. (the " Company ") entered into an Agreement and Plan of Merger (the " Merger Agreement ") with Essence Parent Inc., a Delaware corporation (" Parent "), and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent (" MergerCo "), which provides for the merger of MergerCo with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the " Merger ").
How much did Essence Parent Inc. pay for Esperion Therapeutics, Inc.?
Each CVR will entitle the holder to its pro rata share, in cash, of contingent payments of up to an additional $100 million in the aggregate, without interest and less any applicable tax withholding, upon the achievement of specified milestones during the applicable milestone periods as set forth in the CVR Agreement.
More from the filing
On July 13, 2026, on the terms and subject to the conditions set forth in the Merger Agreement and pursuant to and in accordance with the applicable provisions of the Delaware General Corporation Law (the " DGCL "), the Merger was consummated.
At the effective time of the Merger (the " Effective Time "), the separate corporate existence of MergerCo ceased, and the Company survived the Merger as a wholly owned subsidiary of Parent.
As described above, at the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, (i) Parent completed its previously announced acquisition of the Company, (ii) the Company became a wholly owned subsidiary of Parent and (iii) each share of common stock, par value $0.001 per share, of the Company ("Common Stock") issued and outstanding immediately prior to the Effective Time (other than shares of Common Stock that, immediately prior to the Effective Time, were (a) held by Parent or MergerCo, (b) held by the Company as treasury shares or (c) held by any per
Quoted from Esperion Therapeutics, Inc.'s Form 8-K.
This is the only completed acquisition Essence Parent Inc. reported under Item 2.01 in the last twelve months, as far as the filings of the companies it bought show.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Essence Parent Inc.Look up Essence Parent Inc. first. Finding the company and seeing how much is on record uses no credits.
Look up Essence Parent Inc.Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.